2025 North America Biosimilar Contract Manufacturing Market Revenue Opportunities Report
Description
The 2025 North America Biosimilar Contract Manufacturing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American biosimilar contract manufacturing market are Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., and Biocon. Boehringer Ingelheim offers end-to-end biosimilar services, including mammalian cell culture and recombinant protein production, with a broad global manufacturing network and recent strategic partnerships in the U.S. Lonza provides comprehensive manufacturing solutions leveraging advanced bioprocessing technologies, focusing on scalable, high-quality biologics production. Catalent, a U.S.-based leader, has extensive biologics development and manufacturing capabilities and supports accelerated biosimilar commercialization. Biocon supplies large-scale microbial fermentation and aseptic formulation services through state-of-the-art facilities, with strong expertise in monoclonal antibodies and insulins, addressing key therapeutic areas like oncology and immunology.
These companies benefit from North America's mature biopharmaceutical ecosystem, favorable regulatory frameworks, and increasing acceptance of biosimilars due to patent expirations on blockbuster biologics. The U.S. is the largest regional player, with significant investments in single-use bioreactors and advanced biomanufacturing technologies to meet growing biosimilar demand. Collaborations, such as Boehringer Ingelheim’s partnership with Quallent Pharmaceuticals, reflect the market’s focus on expanding biosimilar availability and reducing healthcare costs. The region’s biosimilar contract manufacturing market is expected to grow substantially, driven by rising chronic disease prevalence, regulatory support, and outsourcing trends among biotech companies aiming to reduce costs and accelerate market entry.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American biosimilar contract manufacturing market are Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., and Biocon. Boehringer Ingelheim offers end-to-end biosimilar services, including mammalian cell culture and recombinant protein production, with a broad global manufacturing network and recent strategic partnerships in the U.S. Lonza provides comprehensive manufacturing solutions leveraging advanced bioprocessing technologies, focusing on scalable, high-quality biologics production. Catalent, a U.S.-based leader, has extensive biologics development and manufacturing capabilities and supports accelerated biosimilar commercialization. Biocon supplies large-scale microbial fermentation and aseptic formulation services through state-of-the-art facilities, with strong expertise in monoclonal antibodies and insulins, addressing key therapeutic areas like oncology and immunology.
These companies benefit from North America's mature biopharmaceutical ecosystem, favorable regulatory frameworks, and increasing acceptance of biosimilars due to patent expirations on blockbuster biologics. The U.S. is the largest regional player, with significant investments in single-use bioreactors and advanced biomanufacturing technologies to meet growing biosimilar demand. Collaborations, such as Boehringer Ingelheim’s partnership with Quallent Pharmaceuticals, reflect the market’s focus on expanding biosimilar availability and reducing healthcare costs. The region’s biosimilar contract manufacturing market is expected to grow substantially, driven by rising chronic disease prevalence, regulatory support, and outsourcing trends among biotech companies aiming to reduce costs and accelerate market entry.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
